Transcarent Acquires Accolade

April 8, 2025

Transcarent has completed its acquisition of Accolade, combining Transcarent's AI-powered WayFinding and Care Experiences with Accolade's health advocacy, expert medical opinion and virtual primary care capabilities. The transaction, valued at approximately $621 million, paid Accolade shareholders $7.03 per share and was financed by General Catalyst and Glen Tullman's 62 Ventures along with other investors and debt provided by J.P. Morgan.

Buyers
Transcarent, General Catalyst, 62 Ventures
Targets
Accolade, Inc.
Sellers
Accolade shareholders
Location
Washington, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.